Psoriasis Market

DelveInsight’s ‘Psoriasis – Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Psoriasis, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, France, Italy, Spain and the United Kingdom), and Japan.

The Psoriasis market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted psoriasis symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Psoriasis symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geographies Covered

• The United States
• EU5
• Japan

Study Period: 2018–2030

Psoriasis Disease Understanding and Treatment Algorithm

Psoriasis Overview

Psoriasis is a chronic, immune-mediated inflammatory skin disease characterized by the presence of papules and plaques occurring most commonly on the elbows, knees, scalp, and lower back, but is not limited to these areas. The World Health Organization recognized psoriasis as a serious non-communicable disease. It has been recognized as skin disease and systemic disease since it also causes psoriatic arthritis and mental disorders.

Psoriasis has both pediatric and adult-onset, with the former accounting for more number of cases. Plaques vary in terms of variable morphology, distribution and severity. Psoriatic patients are frequently categorized into two groups: mild or moderate to severe psoriasis, depending on the clinical severity of the lesions, the percentage of affected body surface area, and patient quality of life.

There are different clinical types of psoriasis, the most common of which is plaque psoriasis. Less common variants of psoriasis include inverse psoriasis, pustular psoriasis, guttate psoriasis and erythrodermic psoriasis.

Although there is no cure for psoriasis, there are multiple effective treatment options, and topical therapy is the standard of care for treatment. Mild to moderate psoriasis can be treated topically with a combination of glucocorticoids, vitamin D analogs, and phototherapy. Systemic treatment is required in moderate to severe cases.

Despite its considerable effect on the quality of life, psoriasis is underdiagnosed and undertreated. A better understanding of the disease and an increase in available treatment options will aid in optimal management and improve patient outcomes in the coming years.

Psoriasis Diagnosis and Treatment

It covers conventional and current medical therapies and diagnosis available in the Psoriasis market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the 7MM.

The DelveInsight Psoriasis market report thoroughly understands Psoriasis symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Psoriasis symptoms of treatment algorithms and treatment guidelines for Psoriasis symptoms in the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan.

Psoriasis Epidemiology

The epidemiology division’s Psoriasis symptoms provide insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Psoriasis epidemiology segmented as the Prevalent cases of Psoriasis in Pediatrics, Prevalent cases of Psoriasis in Adults, Type-specific prevalent case of Psoriasis, Location-specific prevalent cases of Psoriasis and Severity-specific Prevalent cases of psoriasis. The report includes the prevalent psoriasis symptoms in the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

The total prevalent cases of psoriasis in the 7MM were 15,450,712 in 2020.

Psoriasis Drug Chapters

The drug chapter segment of the Psoriasis report encloses the detailed analysis of psoriasis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Psoriasis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

The mainstay of treatment remains Topical treatments – medications applied to the skin. Topicals slow down or normalize excessive cell reproduction and reduce inflammation caused by psoriasis. Topicals are often the first treatment recommended to a newly diagnosed person. Topicals can be purchased over the counter or by prescription. There are several effective topical treatments for psoriasis, many of which can be purchased over the counter (OTC). However, some topicals are only available by prescription from the health care provider.

Major topical agents include corticosteroids, retinoids (tazarotene), and calcineurin inhibitors (tacrolimus), vitamin D analogs (calcipotriene or calcitriol), and combinations (calcipotriol plus betamethasone dipropionate).

Products detail in the report…

Psoriasis Emerging Drugs

Akros Pharma is developing JTE-451 for the treatment of moderate to severe plaque psoriasis in adults. It suppresses the overactive immune response via inhibition of RORγ related to Th17 activation. JTE-451 is currently in Phase II clinical trial for moderate to severe plaque psoriasis.

Psoriasis Market Outlook

The Psoriasis market outlook of the report helps build the detailed comprehension of the historic, current and forecasted Psoriasis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.

This segment gives a thorough detail of Psoriasis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight clearly.

According to DelveInsight, the Psoriasis market in the 7MM is expected to change in the study period 2018–2030.

Key Findings

This section includes a glimpse of the Psoriasis market in the United States. The market size of Psoriasis in the United States was United States USD 12,091 Million in 2020, and the market is estimated to increase during the study period (2018–2030).

The United States Market Outlook

This section provides a total of Psoriasis market size and market size by therapies in the United States.

The pipeline scenario is showing early promise with several therapeutic candidates at different stages of clinical development. Many new therapies for psoriasis are in development, many of which have novel targets and mechanisms of action. Among the biologics, Bimekizumab (UCB) and Tapinarof (Dermavant Sciences) are in the late development stages.

Apart from these, Sonelokimab (Merck) and Vunakizumab (Hengrui Therapeutics) are currently in the Phase II stage of clinical development.

EU-5 Countries: Market Outlook

The total Psoriasis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided.

Bimekizumab (UCB4940) is a novel humanized monoclonal antibody of the immunoglobulin G1 isotype, rationally designed to bind at a similar site on both IL‐17A and IL‐17F conveying dual inhibition of both isoforms. In June 2021, UCB received positive CHMP opinion recommending approval of bimekizumab in the EU for the Treatment of Adults with Moderate to Severe Plaque Psoriasis.

Japan: Market Outlook

The total Psoriasis market size and market size by therapies in Japan are also mentioned.

Psoriasis Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Psoriasis market uptake by drugs, patient uptake by therapies, and drug sales.

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows comparing the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Psoriasis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Psoriasis key players involved in developing targeted therapeutics.

Major players include Bimekizumab (UCB), Tapinarof (Dermavant Sciences), ARQ-151 (Arcutis Biotherapeutics) etc. and being assessed as potential therapies available in the market in the future

Products detail in the report…

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, merger, licensing, and patent details for Psoriasis emerging therapies.

Reimbursement Scenario in Psoriasis

While many individuals wait until their claim has been denied before seeking the services of a Social Security attorney, the patient should consider retaining legal representation before submitting the initial application. By working with an attorney or advocate, the patient will ensure that patient’s claim has sufficient supportive medical evidence and that it will be processed through the Compassionate Allowances program. An attorney will do his or her best to ensure that the patient receives Social Security Disability benefits as quickly as possible and help the patient avoid the lengthy disability appeal process.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Psoriasis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or the Psoriasis market trend. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Psoriasis Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of psoriasis, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
• Comprehensive insight has been provided into the Psoriasis epidemiology and treatment in the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• Additionally, an all-inclusive account of both the current and emerging therapies for psoriasis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Psoriasis market; historical and forecasted is included in the report, covering drug outreach in the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report provides an edge while developing business strategies by understanding trends shaping and driving the global Psoriasis market

Report Highlights

• In the coming years, the Psoriasis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world, which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Psoriasis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for psoriasis. The launch of emerging therapies will significantly impact the Psoriasis market.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for psoriasis.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Psoriasis Report Insights

• Patient Population
• Therapeutic Approaches
• Psoriasis Pipeline Analysis
• Psoriasis Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Psoriasis Report Key Strengths

• 10-year Forecast
• The United States Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Market Size by Country
• Market Size by Therapy

Psoriasis Report Assessment

• Current Treatment Practices
• Unmet Needs
• Emerging Drug Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What was the Psoriasis Market share (%) distribution in 2018, and how it would look like in 2030?
• What would be the Psoriasis total market Size as well as market Size by therapies across the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan during the forecast period (2018–2030)?
• What are the market’s key findings across the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan and historical as well as forecasted epidemiology during the forecast period (2018–2030)?
• At what CAGR, the Psoriasis market is expected to grow by the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan during the forecast period (2018–2030)?
• What would be the Psoriasis market outlook across the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan during the forecast period (2018–2030)?
• What would be the Psoriasis market growth till 2030, and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and unmet needs of psoriasis?
• What is the historical Psoriasis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of psoriasis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM concerning the patient population about psoriasis?
• At what CAGR the population is expected to grow during the forecast period (2018–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of psoriasis?
• What are the current treatment guidelines for treating psoriasis in the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
• What are psoriasis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of psoriasis?
• How many therapies are developed by each company for the treatment of psoriasis?
• How many emerging therapies are in the mid-stage and late stages of development to treat psoriasis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Psoriasis therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for psoriasis and its status?
• What are the key designations that have been granted for the emerging therapies for psoriasis?
• What are the global historical and forecasted market of psoriasis?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Psoriasis market
• To understand the future market competition in the Psoriasis market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Psoriasis in the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Psoriasis market
• To understand the future market competition in the Psoriasis market